Monoclonal Antibodies - Information for Providers

Casirivimab/imdevimab and bamlanivimab/etesevimab were granted emergency use authorization for the treatment of mild to moderate COVID-19. Until the national supply of these monoclonal antibodies (mAbs) is sufficient, the Iowa Department of Public Health and the United States government will help facilitate allocation across Iowa.

Find a COVID-19 Monoclonal Antibody Provider

HHS mAb Site Locator NICA mAb Site Locator

Request COVID-19 Monoclonal Antibodies

Casirivimab/imdevimab and bamlanivimab/etesevimab are available at no cost to healthcare providers. Healthcare providers can submit a request to the Iowa Department of Public Health. This request will be added to a list of eligible recipients for monoclonal antibody products for future allocations. Eligibility is not a guarentee for receiving future allocations of monoclonal antibody products.

Additional information on the distribution process can be found here.

General Resources

Therapeutics Brief 10.5.22 NEW
Therapeutics Brief 9.21.22
Therapeutics Brief 9.7.22
Therapeutics Brief 8.24.22
Therapeutics Brief 8.10.22
HRSA COVID Uninsured Claim
DHS and IME COVID-19 Vaccines and Monoclonal Antibodies Information Letter
HHS Combat COVID Website
National Infusion Center Association COVID-19 Antibody Treatment Resource Center
NIH Treatment Guidelines
Vaccine and Monoclonal Antibodies Guidance: See NIH Treatment Guidelines and Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States
COVID-19 Monoclonal Antibody Therapeutics Digital Toolkit
IDPH Therapeutic Guidance - Anti-Virals
IDPH Therapeutic Guidance - mAb
IDPH Therapeutic Guidance - mAbSp

Bebtelovimab (Eli Lilly)

Questions

For questions, please contact Combat COVID Monoclonal Antibodies Call Center at 877-332-6585.